Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2026)

Tandem Diabetes Care filings provide 7 years of Operating Leases readings, the most recent being $134.4 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 26.33% to $134.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $134.4 million, a 26.33% increase, with the full-year FY2025 number at $134.4 million, up 26.33% from a year prior.
  • Operating Leases hit $134.4 million in Q4 2025 for Tandem Diabetes Care, down from $139.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $143.8 million in Q1 2025 to a low of $3.0 million in Q2 2022.
  • Median Operating Leases over the past 5 years was $116.8 million (2023), compared with a mean of $99.4 million.
  • Biggest five-year swings in Operating Leases: crashed 91.81% in 2022 and later surged 4438.57% in 2023.
  • Tandem Diabetes Care's Operating Leases stood at $23.9 million in 2021, then skyrocketed by 416.36% to $123.5 million in 2022, then decreased by 8.06% to $113.6 million in 2023, then dropped by 6.3% to $106.4 million in 2024, then rose by 26.33% to $134.4 million in 2025.
  • The last three reported values for Operating Leases were $134.4 million (Q4 2025), $139.7 million (Q3 2025), and $120.0 million (Q2 2025) per Business Quant data.